Everolimus in Treating Cutaneous T-cell Lymphoma (CTCL) - This study is no longer recruiting participants.

  • Home
  • Blog
  • Everolimus in Treating Cutaneous T-cell Lymphoma (CTCL) - This study is no longer...

Bookmark and Share

Apr 02

T-Cell Leukemia Lymphoma Foundation

Everolimus in Treating Cutaneous T-cell Lymphoma (CTCL) - This study is no longer recruiting participants.

Posted by T-Cell Leukemia Lymphoma Foundation

CTCL is a rare form of lymphoma of the skin. While early stages are usually confined to the skin, later stages may spread to blood, lymph nodes and other organs. At this point, patients usually require systemic chemo. This study will investigate the effect of everolimus as treatment for recurrent or refractory CTCL. Participation in this study will last as long as the study doctor believes disease has not gotten worse, and patients continue to tolerate the study medication for a maximum of 1 year. Once off the treatment, patients will be followed for two years.

Study Type:    Interventional

Study Design:    

Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:    PHASE II TRIAL OF THE mTOR INHIBITOR EVEROLIMUS IN RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA (CTCL)

Condition:  Cutaneous T-Cell Lymphoma                                        

Intervention:  Drug:  Everolimus                                                                                

Phase:  Phase 2

External Link:  https://clinicaltrials.gov/ct2/show/NCT01637090



Save the Date Save the Date

All Events >